Literature DB >> 29171762

PLK4: a link between centriole biogenesis and cancer.

Radhika Radha Maniswami1, Seema Prashanth1, Archana Venkataramana Karanth1, Sindhu Koushik1, Hemalatha Govindaraj1, Ramesh Mullangi1, Sriram Rajagopal1, Sooriya Kumar Jegatheesan1.   

Abstract

INTRODUCTION: Polo like kinase (PLK) is known to play a pivotal role in various cell cycle processes to perpetuate proper division and growth of the cells. Polo like kinase-4 (PLK4) is one such kinase that appears in low abundance and plays a well-characterized role in centriole duplication. PLK4 deregulation (i.e. both overexpression and depletion of PLK4), leads to altered mitotic fidelity and thereby triggers tumorigenesis. Hence, over the last few years PLK4 has emerged as a potential therapeutic target for the treatment of various advanced cancers. Areas covered: In this review, we discuss the basic structure, expression, localization and functions of PLK4 along with its regulation by various proteins. We also discuss the role of altered PLK4 activity in the onset of cancer and the current pre-clinical and clinical inhibitors to regulate PLK4. Expert opinion: PLK4 mediated centriole duplication has a crucial role in maintaining mitotic correctness in normal cells, while its deregulation has a greater impact on genesis of cancer. Henceforth, a deep knowledge of the PLK4 levels, its role and interactions with various proteins in cancer is required to design effective inhibitors for clinical use.

Entities:  

Keywords:  945; CFI-400; PLK4; centriole duplication

Mesh:

Substances:

Year:  2017        PMID: 29171762     DOI: 10.1080/14728222.2018.1410140

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  20 in total

1.  PLK4 deubiquitination by Spata2-CYLD suppresses NEK7-mediated NLRP3 inflammasome activation at the centrosome.

Authors:  Xiao-Dong Yang; Wenguo Li; Shuangyan Zhang; Dandan Wu; Xiaoli Jiang; Rong Tan; Xiaoyin Niu; Qijun Wang; Xuefeng Wu; Zhiduo Liu; Lin-Feng Chen; Jun Qin; Bing Su
Journal:  EMBO J       Date:  2019-11-25       Impact factor: 11.598

Review 2.  It takes two (centrioles) to tango.

Authors:  Tomer Avidor-Reiss; Emily L Fishman
Journal:  Reproduction       Date:  2019-02       Impact factor: 3.906

3.  Polo-like kinase 4 is associated with advanced TNM stages and reduced survival and its inhibition improves chemosensitivity in colorectal cancer.

Authors:  Zhengang Duan; Lei Cai; Jin Cao; Wei Wu
Journal:  Oncol Lett       Date:  2022-06-20       Impact factor: 3.111

4.  Hypoxia Drives Centrosome Amplification in Cancer Cells via HIF1α-dependent Induction of Polo-Like Kinase 4.

Authors:  Karuna Mittal; Jaspreet Kaur; Shaligram Sharma; Nivya Sharma; Guanhao Wei; Ishita Choudhary; Precious Imhansi-Jacob; Nagini Maganti; Shrikant Pawar; Padmashree Rida; Michael S Toss; Mohammed Aleskandarany; Emiel A Janssen; Håvard Søiland; Meenakshi V Gupta; Michelle D Reid; Emad A Rakha; Ritu Aneja
Journal:  Mol Cancer Res       Date:  2022-04-01       Impact factor: 6.333

Review 5.  Targeting the cell cycle in breast cancer: towards the next phase.

Authors:  K L Thu; I Soria-Bretones; T W Mak; D W Cescon
Journal:  Cell Cycle       Date:  2018-09-11       Impact factor: 4.534

Review 6.  PLK4: a promising target for cancer therapy.

Authors:  Yi Zhao; Xin Wang
Journal:  J Cancer Res Clin Oncol       Date:  2019-09-06       Impact factor: 4.553

Review 7.  Polo-like kinases and acute leukemia.

Authors:  Oksana Goroshchuk; Iryna Kolosenko; Linda Vidarsdottir; Alireza Azimi; Caroline Palm-Apergi
Journal:  Oncogene       Date:  2018-08-13       Impact factor: 9.867

8.  Direct interaction between CEP85 and STIL mediates PLK4-driven directed cell migration.

Authors:  Yi Liu; Jaeyoun Kim; Reuben Philip; Vaishali Sridhar; Megha Chandrashekhar; Jason Moffat; Mark van Breugel; Laurence Pelletier
Journal:  J Cell Sci       Date:  2020-04-23       Impact factor: 5.285

Review 9.  Role of Polo-Like Kinase 4 (PLK4) in Epithelial Cancers and Recent Progress in its Small Molecule Targeting for Cancer Management.

Authors:  Debra R Garvey; Gagan Chhabra; Mary A Ndiaye; Nihal Ahmad
Journal:  Mol Cancer Ther       Date:  2021-01-05       Impact factor: 6.009

10.  Clinical Significance of Polo-Like Kinase 4 as a Marker for Advanced Tumor Stage and Dismal Prognosis in Patients With Surgical Gastric Cancer.

Authors:  Ting Cao; Shijie Yi; Xuefeng Yang; Qing Wu
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.